The well-established oncogenic role of cell cycle proteins within the cyclin D/CDK4/CDK6/RB network in NB [29] contrasts with the variability in the CDKN2A status (i.e. either deletions or amplifications), and underscores the need for molecular-driven personalization. Here, CDKN2A is linked to neuroblastoma.